CD BioSciences provides one-stop services for lead antibody discovery for the treatment of pancreatic cancer (PC), from antigen preparation (such as peptides and protein molecules) to animal immunization and antibody screening. Our antibody drug development platform has been proven to be reliable and effective. Our team of experienced scientists, researchers and technicians can provide flexible and scalable services to meet the specific needs of our clients at every stage of their projects.
Three major technical support
|Antibody drug lead generation platforms at CD BioSciences|
|Technologies||Descriptions||Antibody Source||Affinity||Screening Duration||Advantages|
|Hybridoma technology||Hybridoma technology is one of the most commonly used methods for producing monoclonal antibodies, relying on hybridoma cell lines (produced by fusion of antibody-producing B lymphocytes and immortalized myeloma cell lines) to produce monoclonal antibodies against specific antigens in vivo or in vitro.||Mice or Human||High||Months||-A well-developed method
-Producing antibody molecules with high affinity
|Human antibody library||We have established a fully human antibody library and are continuously expanding it. The library consists of a human natural library and a human synthetic library, which can meet the needs of diversity and affinity in the discovery process of antibody lead molecules at the same time.||Human||Relatively Lower||Months||-Direct access to fully human antibody sequences without animal immunizations
-Screen through natural & synthetic libraries simultaneously
-Diversified panning & screening strategies
|Single B-cell screening||Also known as single B cell cloning technology, is a microsystem-based screening method. The technique isolates, screens, sorts, and evaluates B cells, avoiding the steps of cell fusion and library construction. In addition, this method is usually integrated with a high-throughput platform that enables analysis in an efficient manner.||Mice or Human||High||Days||-Minimal diversity loss, forward functional screening
-Short screening time cycle
-Outstanding advantages for challenging targets
The service offering at CD BioSciences
- Antigen preparation
We have years of experience in peptide synthesis and protein expression, and with our perfect quality control system, we can customize antigen preparation according to project requirements and deliver quickly. Our in-depth understanding of the complex biology, microenvironment and immune system of the PC can help researchers find and prepare relevant antigens that are expressed at high levels at different stages of the disease. Using biochemical, flow cytometric, mass spectrometric, and CRISPR/Cas9-mediated knockout methods, we can further identify the cognate antigens of the antibodies.
Fig. 1 Summary of key signalling pathways in the progression of PDAC that have been targeted by monoclonal antibody (mAb) therapy. (Boland, Anna J., et al., 2021)
- Animal immunization and screening
We provide standard and rapid mouse monoclonal antibody preparation services, and standard and rapid rabbit monoclonal antibody preparation services.
- Monoclonal antibody (mAb) sequencing
Antibody sequence data is essential for any antibody engineering or humanization development. We provide mAb sequencing services, including variable region cloning and sequencing, leader sequence & variable domain cloning and sequencing, and full-length antibody cloning and sequencing services, to fully meet your selected antibody sequencing needs for different sample types.
- Generation of fully human antibody
Based on transgenic mouse platforms (humanized mice are conducted on the hybridoma platform), we can produce mAbs with higher affinity and efficacy and lower immunogenicity.
If you are interested in our services, please contact us for more details. Our clients have direct access to our staff and prompt feedback on their inquiries.
- Boland, Anna J., et al. "Antibody therapy in pancreatic cancer: mAb-ye we’re onto something?." Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1876.1 (2021): 188557.